In August 2004, I was 42 and going through the annual checkup routine. I felt fine and had no reason to suspect anything was starting to go wrong. I was called back twice to have more labs done.
In the past few months, 2 main streams of research have dominated the panorama of myelodysplastic syndrome (MDS) investigations: deepening the insight into the pathogenic role, hierarchy, and prognostic effect of somatic mutations and, as a consequence, into the effect of inherited congenital predisposing conditions and the second, quite interlinked with the first, analyzing inflammation and innate immunity in patients with MDS.
This PDQ cancer information summary has current information about the treatment of